Compare ARMOUR Residential REIT, Inc. (ARR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Zoetis Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.74 (market cap $2.07B), while Zoetis Inc trades at $72.43 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 15× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays the higher dividend (17.28%). Which is the better fit depends on your goals.
| ARR | ZTS | |
|---|---|---|
Market Cap | $2.07B | $31.14B |
Sector | Financials | Health |
52-Week High | $19.12 | $156.76 |
52-Week Low | $14.05 | $71.91 |
Dividend Yield | 17.28% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARMOUR Residential REIT (ARR) trades at $16.54, down 0.84% on the day, amid a bearish technical signal. The stock shows a low P/E of 3.78 and trades below book value (P/B 0.91), suggesting potential undervaluation. Recent earnings were mixed, with a Q2 2026 beat but a Q4 2025 miss. The company maintains a high net income margin of 97.43% and consistent dividend payments, with the latest being $0.24 per share. Cash flow from operations improved to $319 million in 2026, though investing outflows remain high.
ARR presents a value opportunity with strong profitability and dividends, but faces risks from volatile earnings, high investing cash outflows, and a bearish technical outlook. Analyst sentiment is mixed, with 60% hold ratings. The stock's appeal hinges on sustained dividend payments and earnings stability amid interest rate sensitivity.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
